202 related articles for article (PubMed ID: 38138214)
41. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
[TBL] [Abstract][Full Text] [Related]
42. A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.
Hanna GJ; ONeill A; Cutler JM; Flynn M; Vijaykumar T; Clark JR; Wirth LJ; Lorch JH; Park JC; Mito JK; Lohr JG; Kaufman J; Burr NS; Zon LI; Haddad RI
Oral Oncol; 2021 Aug; 119():105366. PubMed ID: 34091189
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
44. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literature.
Olmos M; Lutz R; Büntemeyer TO; Glajzer J; Nobis CP; Ries J; Möst T; Eckstein M; Hecht M; Gostian AO; Erdmann M; Foerster Y; Kesting M; Weber M
Front Immunol; 2022; 13():970823. PubMed ID: 36389668
[TBL] [Abstract][Full Text] [Related]
45. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
46. Adenoid cystic carcinoma of head and neck: A retrospective clinical analysis of a single institution.
Chang CF; Hsieh MY; Chen MK; Chou MC
Auris Nasus Larynx; 2018 Aug; 45(4):831-837. PubMed ID: 29653784
[TBL] [Abstract][Full Text] [Related]
47. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
[TBL] [Abstract][Full Text] [Related]
48. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
Li J; Luo Z; Jiang S; Li J
Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V; Herrera-Gómez RG; Szturz P; Espeli V; Siano M
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671550
[TBL] [Abstract][Full Text] [Related]
50. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
51. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up.
Ishida E; Ogawa T; Rokugo M; Ishikawa T; Wakamori S; Ohkoshi A; Usubuchi H; Higashi K; Ishii R; Nakanome A; Katori Y
Head Face Med; 2020 Jul; 16(1):14. PubMed ID: 32616049
[TBL] [Abstract][Full Text] [Related]
52. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
53. Inflammation and malnutrition as markers of poor outcomes in head and neck cancer patients treated with nivolumab.
Arihara Y; Takada K; Murase K; Kawamura K; Kakiuchi A; Kurose M; Sasaki T; Ogi K; Yamazaki M; Miyazaki A; Kato J; Takano K
Acta Otolaryngol; 2023 Aug; 143(8):714-720. PubMed ID: 37537940
[TBL] [Abstract][Full Text] [Related]
54. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
Persson M; Andrén Y; Moskaluk CA; Frierson HF; Cooke SL; Futreal PA; Kling T; Nelander S; Nordkvist A; Persson F; Stenman G
Genes Chromosomes Cancer; 2012 Aug; 51(8):805-17. PubMed ID: 22505352
[TBL] [Abstract][Full Text] [Related]
55. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.
de Sousa LG; Neto FL; Lin J; Ferrarotto R
Curr Oncol Rep; 2022 May; 24(5):621-631. PubMed ID: 35212920
[TBL] [Abstract][Full Text] [Related]
56. MYB alternative promoter activity is increased in adenoid cystic carcinoma metastases and is associated with a specific gene expression signature.
Huang J; Fehr A; Jäwert F; Nilsson JA; Morris LGT; Stenman G; Andersson MK
Oral Oncol; 2024 Apr; 151():106763. PubMed ID: 38493544
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
Swiecicki PL; Bellile EL; Brummel CV; Brenner JC; Worden FP
Cancer; 2021 Jan; 127(2):219-228. PubMed ID: 33079405
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
[TBL] [Abstract][Full Text] [Related]
59. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
60. Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.
Gavrielatou N; Vathiotis I; Aung TN; Shafi S; Burela S; Fernandez AI; Moutafi M; Burtness B; Economopoulou P; Anastasiou M; Foukas P; Psyrri A; Rimm DL
Cancer Res Commun; 2023 Apr; 3(4):558-563. PubMed ID: 37057033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
